Tenax Therapeutics (NASDAQ:TENX) Upgraded to Strong-Buy at Leerink Partnrs

Leerink Partnrs upgraded shares of Tenax Therapeutics (NASDAQ:TENX) to a strong-buy rating in a research report sent to investors on Thursday, Zacks.com reports.

A number of other research analysts have also commented on TENX. Leerink Partners assumed coverage on Tenax Therapeutics in a research report on Thursday. They issued an “outperform” rating and a $16.00 price objective on the stock. StockNews.com assumed coverage on Tenax Therapeutics in a research report on Thursday, September 26th. They issued a “sell” rating for the company. Guggenheim initiated coverage on Tenax Therapeutics in a report on Monday, October 14th. They set a “buy” rating and a $16.00 price objective for the company. Finally, William Blair assumed coverage on shares of Tenax Therapeutics in a research note on Monday, September 30th. They issued an “outperform” rating on the stock. One analyst has rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $170.67.

Tenax Therapeutics Trading Down 0.6 %

Shares of NASDAQ TENX opened at $4.75 on Thursday. Tenax Therapeutics has a 12-month low of $2.77 and a 12-month high of $61.20. The firm’s 50-day simple moving average is $3.79 and its 200 day simple moving average is $3.58.

Tenax Therapeutics (NASDAQ:TENX) last announced its earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.99) by $0.16. Research analysts expect that Tenax Therapeutics will post -6.75 EPS for the current fiscal year.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.